Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05352828 · ClinicalTrials.gov registry record · Phase 1
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
A Phase 1 study of Classical Hodgkin Lymphoma and Hodgkin Disease Recurrent, sponsored by Tessa Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT05352828: Active Phase 1 study of Classical Hodgkin Lymphoma and Hodgkin Disease Recurrent, sponsored by Tessa Therapeutics.
NCT05352828 is a Phase 1 study of Classical Hodgkin Lymphoma and Hodgkin Disease Recurrent that is active but no longer recruiting, run by Tessa Therapeutics. The registered enrollment target is 15 participants, below the 78-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05352828, a Phase 1 study of Classical Hodgkin Lymphoma and Hodgkin Disease Recurrent, is active but no longer recruiting, sponsored by Tessa Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.
Primary Outcome
DLT
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Nivolumab
- DRUG Bendamustine
- DRUG Autologous CD30.CAR-T
Study Locations (5)
Texas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Center - Houston
California
- City of Hope National Medical Center - Duarte
Florida
- University of Miami - Miami
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2037-12-15 |
| Phase | Phase 1 |
What the registry record for NCT05352828 still lists
NCT05352828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 78-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Classical Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Fludarabine is the first listed.
NCT05352828 lists 5 locations in 4 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05352828 about?
NCT05352828 is a clinical study titled "Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy". This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Ho...
What is the current status of trial NCT05352828?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-07-25. Estimated completion is 2037-12-15.
What conditions does trial NCT05352828 study?
This clinical trial studies the following conditions: Classical Hodgkin Lymphoma, Hodgkin Disease Recurrent, Hodgkin Disease Refractory.
What interventions are being tested in trial NCT05352828?
The interventions under investigation include: Fludarabine (DRUG), Nivolumab (DRUG), Bendamustine (DRUG), Autologous CD30.CAR-T (DRUG).
Who is sponsoring clinical trial NCT05352828?
This trial is sponsored by Tessa Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05352828 being conducted?
This trial has 5 study locations across California, Florida, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classical Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05352828's enrollment target sits among peer trials
15 7th of 8 higher than 2 of 8 other Classical Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Classical Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
RECRUITING · Phase 1
-
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Itacitinib + Everolimus in Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Phase Ib of L-NMMA and Pembrolizumab
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI